NASDAQ$CAPR
Capricor Therapeutics Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Capricor reported a net loss for Q3 2020 and provided a corporate update, highlighting progress in exosome platform technology, Duchenne Muscular Dystrophy program, and CAP-1002 for COVID-19.
Capricor Therapeutics reported a net loss of $3.9 million, or $0.20 per share, for the third quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled approximately $35.3 million as of September 30, 2020.
- Announced positive preclinical data for multivalent exosome-mRNA vaccine for COVID-19.
- Developing a safe, non-toxic exosome formulation capable of delivering functional mRNA in vitro and in vivo.
- In discussions with the FDA on next steps for the Duchenne Muscular Dystrophy program.
- Patient screening is underway in the randomized, double-blind, placebo-controlled INSPIRE study for CAP-1002 for COVID-19.
Headline financials
Revenue & EPS history
Capricor · Revenue · Quarterly
$16.9K
Forward guidance
The Company expects significant pipeline expansion and will be seeking partnering opportunities in the months ahead to further cement its rebranding.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2020
-0.8%
Avg return
Earnings day
-1.3%
Avg return
5 days after
+7.0%
Avg return
30 days after
39%
19 / 49 earnings
Positive
+25.4%
Q2 2023
Best reaction
-20.4%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.5% | -10.9% | -17.8% | |
| Q4 2025 | +1.0% | -7.5% | -6.6% | |
| Q3 2025 | +10.8% | +0.7% | +388.8% | |
| Q1 2025 | +10.0% | +15.0% | +31.1% | |
| Q4 2024 | +17.5% | +10.3% | -7.9% | |
| Q3 2024 | +2.2% | +1.5% | -26.7% | |
| Q2 2024 | -0.8% | +0.3% | +4.3% | |
| Q1 2024 | -1.9% | +17.0% | -4.5% | |
| Q4 2023 | +5.5% | +14.5% | +56.8% | |
| Q3 2023 | +13.0% | +7.0% | +49.3% | |
| Q2 2023 | +25.4% | +32.2% | +32.6% | |
| Q1 2023 | -1.2% | +3.9% | +15.2% | |
| Q4 2022 | -1.7% | -3.4% | -5.6% | |
| Q3 2022 | -3.4% | -13.2% | -19.1% | |
| Q2 2022 | +14.5% | +6.1% | +28.0% | |
| Q1 2022 | -5.4% | -1.9% | +28.2% | |
| Q4 2021 | -8.1% | -9.0% | -22.9% | |
| Q3 2021 | -4.6% | -6.0% | -13.0% | |
| Q2 2021 | -8.4% | -10.0% | +11.1% | |
| Q1 2021 | +6.8% | +13.6% | +31.3% | |
| Q4 2020 | -4.8% | -11.4% | -19.3% | |
| Q3 2020 | -7.2% | -9.0% | -10.4% | |
| Q2 2020 | -20.4% | -18.0% | -42.3% | |
| Q1 2020 | -10.1% | -18.9% | -33.3% | |
| Q4 2019 | +0.9% | -0.9% | +34.2% | |
| Q3 2019 | -14.1% | -25.0% | -48.0% | |
| Q2 2019 | -9.3% | -23.6% | -34.2% | |
| Q1 2019 | -2.4% | -23.8% | -10.7% | |
| Q4 2018 | -16.1% | +14.3% | -10.7% | |
| Q3 2018 | -4.3% | -1.1% | -40.9% | |
| Q2 2018 | -8.3% | -15.0% | -5.0% | |
| Q1 2018 | -2.2% | -3.0% | -6.0% | |
| Q4 2017 | +2.8% | -0.6% | -11.7% | |
| Q3 2017 | +10.5% | +37.5% | -11.5% | |
| Q2 2017 | -7.1% | -6.2% | -8.8% | |
| Q1 2017 | -13.8% | -21.6% | -33.6% | |
| Q4 2016 | +8.0% | +3.3% | +5.0% | |
| Q3 2016 | -2.5% | +7.5% | -4.3% | |
| Q2 2016 | +4.0% | +4.0% | +10.8% | |
| Q1 2016 | +2.1% | — | — | |
| Q4 2015 | +4.0% | — | — | |
| Q1 2012 | -4.3% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | +4.5% | — | — | |
| Q1 2011 | -13.8% | — | — | |
| Q4 2010 | -3.2% | — | — | |
| Q3 2010 | -13.2% | — | — | |
| Q2 2010 | +18.4% | — | — | |
| Q1 2010 | -3.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro